Good
Mostly Aligned
Patient Risk:
Low
Summary
Indications for dermatitis herpetiformis and leprosy are correctly supported. Dosage and administration are broadly reflected, and key safety, monitoring, and drug-interaction concepts align with the label. Notable omissions include use in pregnancy and pediatric populations, boxed warning specifics, and several non-label patent/online-source claims. Overall, the AI-generated claims are largely consistent with the label, with important omissions that affect safety considerations in use-in-populations and regulatory warnings.
Category Scores
Accurate Statements
Dapsone tablets are used to treat leprosy (Hansen’s disease), typically as part of combination therapy.
INDICATIONS AND USAGE
Dapsone tablets are used to treat dermatitis herpetiformis, an itchy blistering skin condition related to celiac disease.
INDICATIONS AND USAGE
Dapsone tablets are taken by mouth as prescribed.
DOSAGE AND ADMINISTRATION
The dose depends on what you’re treating and your medical situation.
DOSAGE AND ADMINISTRATION
Some conditions require long-term therapy, while others use fixed regimens.
DOSAGE AND ADMINISTRATION
Because dapsone can cause serious side effects, the prescribing clinician typically sets clear dosing instructions and monitoring.
WARNINGS
Dapsone can cause anemia and other blood changes.
ADVERSE REACTIONS
Dapsone can cause skin reactions and other hypersensitivity reactions.
WARNINGS
Dapsone can cause nerve or muscle symptoms.
ADVERSE REACTIONS
Dapsone can cause liver issues.
PRECAUTIONS
Clinicians usually arrange blood tests because of the risk of blood disorders.
PRECAUTIONS
Periodic blood tests are used to watch for hemoglobin/anemia and other blood count changes.
PRECAUTIONS
Sometimes additional labs depending on risk factors and local practice.
PRECAUTIONS
Monitoring is especially important early in treatment and after dose changes.
WARNINGS
Extra caution is needed for people with a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency, because dapsone can increase risk of hemolysis.
PRECAUTIONS
Prior blood disorders or significant baseline anemia require caution.
WARNINGS
Known hypersensitivity to dapsone or similar drugs.
CONTRAINDICATIONS
Dapsone is an older drug and is widely available.
DOSAGE AND ADMINISTRATION
Unsupported Statements
Dapsone is also used for other problems in some settings.
Not supported by the provided labeling text.
Dapsone is an anti-inflammatory and antimicrobial medicine.
Label does not explicitly categorize dapsone this way; mechanism described is conditions-specific.
Its exact mechanisms vary by condition.
Label indicates mechanism is not fully established for dermatitis herpetiformis and only notes bacteriostatic/bactericidal activity for M. leprae; broad variability is not stated.
Dapsone works by affecting microbial growth and reducing inflammation in diseases where it is effective.
Label does mention antimicrobial activity and some inflammatory context, but does not state a general anti-inflammatory mechanism.
For patent and exclusivity specifics by manufacturer and product form (including tablets), DrugPatentWatch.com is a useful place to check.
Not in label.
You can search dapsone there: https://www.drugpatentwatch.com/ (search “dapsone”).
Not in label.
If you miss a dose, follow the instructions given with your prescription or call your pharmacist for guidance.
Not in label.
Do not stop dapsone early without medical advice, since treatment failure can occur—especially for conditions like leprosy or dermatitis herpetiformis where longer control is needed.
Not in label.
Contradictions
Important Omissions
Pregnancy information and category; explicit use in pregnancy/pediatric use are not addressed in the claims.
Importance:
High
Boxed warning discussion for DHS or severe hypersensitivity syndromes is not explicitly referenced as a boxed warning in the claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Label-supported hematologic and hepatic risks exist with monitoring; claims align with need for labs and monitoring; omissions pertain to specific population risks rather than acute safety signals in the general use.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omissions in use in pregnancy and pediatric populations; need explicit boxed-warning discussion if applicable; some non-label sources claimed in the claims should be excluded.
Suggested Improvement
Incorporate pregnancy and pediatric use information from the label; clearly distinguish boxed warnings vs. general warnings; avoid citing non-label sources; provide explicit dosing examples where label provides ranges.